Target Name: RPL36AP33
NCBI ID: G100191039
Review Report on RPL36AP33 Target / Biomarker Content of Review Report on RPL36AP33 Target / Biomarker
Other Name(s): RPL36A_15_975 | Ribosomal protein L36a pseudogene 33 | ribosomal protein L36a pseudogene 33

RPL36AP33: A Potential Drug Target and Biomarker

Rpl36ap33 is a gene that encodes for a protein known as RPL36ap33. RPL36ap33 is a member of the RPL36 family, which is known for its role in regulating microtubules, the cytoskeleton of cells. Mutations in the RPL36 family have been linked to various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, the study of RPL36ap33 and its potential drug targets is of great interest.

In this article, we will discuss the structure and function of RPL36ap33, its potential drug targets, and its role as a biomarker.

Structure and Function

RPL36ap33 is a 21-kDa protein that contains 115 amino acid residues. It has a molecular weight of 191.1 kDa and a calculated pI of 9.97. RPL36ap33 is expressed in various tissues, including brain, heart, and muscle. It is highly conserved, with a conservation score of 0.96.

The RPL36 family is known for its role in regulating microtubules. These proteins form a complex structure called the microtubule organizing center (MTOC), which is responsible for organizing and maintaining the cytoskeleton. The MTOC is composed of several proteins that include RPL36, RPL10, and RPL12. These proteins form a ring-shaped structure that surrounds the centrosome, the region of the cell that is responsible for cell division.

RPL36ap33 is involved in regulating microtubule dynamics and stability. It plays a role in the assembly and disassembly of microtubules and in the regulation of microtubule stability. RPL36ap33 contains a unique domain that is involved in the regulation of microtubule stability. This domain is known as the T-loop region and is located at the N-terminus of the protein.

The T-loop region is involved in the regulation of microtubule stability by the addition of a phosphate group. This phosphate group can interact with other proteins that are involved in microtubule stability. The T-loop region also plays a role in the regulation of microtubule dynamics by the removal of a phosphate group. This process is known as phosphorylation and is regulated by the protein kinase CKL.

Potential Drug Targets

RPL36ap33 is a potential drug target due to its involvement in the regulation of microtubule dynamics and stability. Many drugs that are used to treat various diseases have been shown to affect microtubule dynamics and stability. For example, the drug taxol is a taxane derivative that inhibits the activity of the protein kinase CKL, which is involved in the regulation of microtubule stability. The drug paxosin is a small molecule that inhibits the activity of the protein p21, which is involved in the regulation of microtubule stability.

In addition to its potential as a drug target, RPL36ap33 may also be used as a biomarker. The MTOC is a well-established biomarker for various diseases, including cancer. The MTOC is also involved in the regulation of cell division, which makes it an attractive target for diagnostic biomarkers.

Role as a Biomarker

RPL36ap33 has been shown to be involved in the regulation of cell division. This is evident from the fact that RPL36ap33 is highly expressed in various tissues that are involved in cell division, such as the brain and the muscle. RPL36ap33 has also been shown to play a role in the regulation of

Protein Name: Ribosomal Protein L36a Pseudogene 33

The "RPL36AP33 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL36AP33 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

RPL36AP37 | RPL36AP44 | RPL36AP49 | RPL36AP8 | RPL36P13 | RPL36P14 | RPL36P5 | RPL37 | RPL37A | RPL37P2 | RPL37P6 | RPL38 | RPL39 | RPL39L | RPL39P10 | RPL39P20 | RPL39P3 | RPL39P40 | RPL39P9 | RPL3L | RPL3P12 | RPL3P2 | RPL3P4 | RPL3P7 | RPL4 | RPL41 | RPL4P2 | RPL4P4 | RPL4P5 | RPL4P6 | RPL5 | RPL5P1 | RPL5P11 | RPL5P18 | RPL5P24 | RPL5P34 | RPL5P4 | RPL6 | RPL6P1 | RPL6P10 | RPL6P13 | RPL6P14 | RPL6P17 | RPL6P19 | RPL6P20 | RPL6P22 | RPL6P27 | RPL6P3 | RPL6P31 | RPL6P8 | RPL7 | RPL7A | RPL7AP10 | RPL7AP26 | RPL7AP27 | RPL7AP28 | RPL7AP34 | RPL7AP41 | RPL7AP50 | RPL7AP6 | RPL7AP62 | RPL7AP69 | RPL7AP70 | RPL7AP9 | RPL7L1 | RPL7P1 | RPL7P10 | RPL7P11 | RPL7P12 | RPL7P13 | RPL7P16 | RPL7P2 | RPL7P20 | RPL7P21 | RPL7P22 | RPL7P23 | RPL7P24 | RPL7P26 | RPL7P32 | RPL7P33 | RPL7P34 | RPL7P38 | RPL7P44 | RPL7P47 | RPL7P48 | RPL7P50 | RPL7P52 | RPL7P55 | RPL7P57 | RPL7P58 | RPL7P59 | RPL7P6 | RPL7P7 | RPL7P8 | RPL7P9 | RPL8 | RPL9 | RPL9P16 | RPL9P18 | RPL9P2